Autologous Mesenchymal Stem Cell Therapy in Progressive Supranuclear Palsy: a Randomized, Double-blind, Controlled Clinical Trial View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2012-2014

ABSTRACT

There is evidence suggesting that stem cells harvested from the bone marrow and transplanted into the brain may be effective in slowing down the progression of parkinsonism. Mesenchymal stem cells are able to produce growth factors that provide support to diseased nervous cells. In this study mesenchymal stem cells will be harvested from the bone marrow, cultivated in a test tube so that they multiply and then infused into the arteries that supply blood to the brain in 20 patients suffering from a rare form of parkinsonism, Progressive Supranuclear Palsy. Each patient will undergo two infusions, one with the stem cells and one without, at an interval of 6 months. The sequence of the two infusions will be assigned randomly; patients and assessors will not know the sequence (double-blind). Patients will be followed-up for up to 1 year after the last infusion, with regular assessments to assess safety, efficacy on motor and cognitive functions, and effects on the brain by neuroimaging techniques. The study has a preliminary phase with 5 patients all given stem cell therapy alone, designed to assess safety More... »

URL

https://clinicaltrials.gov/show/NCT01824121

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3120", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "There is evidence suggesting that stem cells harvested from the bone marrow and transplanted into the brain may be effective in slowing down the progression of parkinsonism. Mesenchymal stem cells are able to produce growth factors that provide support to diseased nervous cells. In this study mesenchymal stem cells will be harvested from the bone marrow, cultivated in a test tube so that they multiply and then infused into the arteries that supply blood to the brain in 20 patients suffering from a rare form of parkinsonism, Progressive Supranuclear Palsy. Each patient will undergo two infusions, one with the stem cells and one without, at an interval of 6 months. The sequence of the two infusions will be assigned randomly; patients and assessors will not know the sequence (double-blind). Patients will be followed-up for up to 1 year after the last infusion, with regular assessments to assess safety, efficacy on motor and cognitive functions, and effects on the brain by neuroimaging techniques. The study has a preliminary phase with 5 patients all given stem cell therapy alone, designed to assess safety", 
    "endDate": "2014-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01824121", 
    "keywords": [
      "mesenchymal stem cell therapy", 
      "progressive supranuclear palsy", 
      "Double-Blind", 
      "controlled clinical trial", 
      "evidence", 
      "stem cell", 
      "bone marrow", 
      "brain", 
      "Parkinsonian Disorder", 
      "Mesenchymal Stromal Cell", 
      "growth factor", 
      "cell", 
      "tube", 
      "artery", 
      "supply blood", 
      "patient", 
      "rare form", 
      "infusion", 
      "interval", 
      "sequence", 
      "assessor", 
      "followed-up", 
      "regular assessment", 
      "efficacy", 
      "motor", 
      "cognitive function", 
      "neuroimaging technique", 
      "preliminary phase", 
      "stem cell therapy"
    ], 
    "name": "Autologous Mesenchymal Stem Cell Therapy in Progressive Supranuclear Palsy: a Randomized, Double-blind, Controlled Clinical Trial", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01824121"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00014.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.414818.0", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.414527.1", 
        "type": "Organization"
      }
    ], 
    "startDate": "2012-12-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/1479-5876-12-14", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005915790", 
          "https://doi.org/10.1186/1479-5876-12-14"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12967-016-0880-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041989489", 
          "https://doi.org/10.1186/s12967-016-0880-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01824121"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01824121'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01824121'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01824121'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01824121'


 

This table displays all metadata directly associated to this object as RDF triples.

61 TRIPLES      16 PREDICATES      48 URIs      38 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01824121 schema:about anzsrc-for:3053
2 anzsrc-for:3120
3 schema:description There is evidence suggesting that stem cells harvested from the bone marrow and transplanted into the brain may be effective in slowing down the progression of parkinsonism. Mesenchymal stem cells are able to produce growth factors that provide support to diseased nervous cells. In this study mesenchymal stem cells will be harvested from the bone marrow, cultivated in a test tube so that they multiply and then infused into the arteries that supply blood to the brain in 20 patients suffering from a rare form of parkinsonism, Progressive Supranuclear Palsy. Each patient will undergo two infusions, one with the stem cells and one without, at an interval of 6 months. The sequence of the two infusions will be assigned randomly; patients and assessors will not know the sequence (double-blind). Patients will be followed-up for up to 1 year after the last infusion, with regular assessments to assess safety, efficacy on motor and cognitive functions, and effects on the brain by neuroimaging techniques. The study has a preliminary phase with 5 patients all given stem cell therapy alone, designed to assess safety
4 schema:endDate 2014-12-01T00:00:00Z
5 schema:keywords Double-Blind
6 Mesenchymal Stromal Cell
7 Parkinsonian Disorder
8 artery
9 assessor
10 bone marrow
11 brain
12 cell
13 cognitive function
14 controlled clinical trial
15 efficacy
16 evidence
17 followed-up
18 growth factor
19 infusion
20 interval
21 mesenchymal stem cell therapy
22 motor
23 neuroimaging technique
24 patient
25 preliminary phase
26 progressive supranuclear palsy
27 rare form
28 regular assessment
29 sequence
30 stem cell
31 stem cell therapy
32 supply blood
33 tube
34 schema:name Autologous Mesenchymal Stem Cell Therapy in Progressive Supranuclear Palsy: a Randomized, Double-blind, Controlled Clinical Trial
35 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01824121
36 schema:sdDatePublished 2019-03-07T15:24
37 schema:sdLicense https://scigraph.springernature.com/explorer/license/
38 schema:sdPublisher N4d3a71781b854ae6af18985facff08f2
39 schema:sponsor https://www.grid.ac/institutes/grid.414527.1
40 https://www.grid.ac/institutes/grid.414818.0
41 schema:startDate 2012-12-01T00:00:00Z
42 schema:subjectOf sg:pub.10.1186/1479-5876-12-14
43 sg:pub.10.1186/s12967-016-0880-2
44 schema:url https://clinicaltrials.gov/show/NCT01824121
45 sgo:license sg:explorer/license/
46 sgo:sdDataset clinical_trials
47 rdf:type schema:MedicalStudy
48 N4d3a71781b854ae6af18985facff08f2 schema:name Springer Nature - SN SciGraph project
49 rdf:type schema:Organization
50 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
51 rdf:type schema:DefinedTerm
52 anzsrc-for:3120 schema:inDefinedTermSet anzsrc-for:
53 rdf:type schema:DefinedTerm
54 sg:pub.10.1186/1479-5876-12-14 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005915790
55 https://doi.org/10.1186/1479-5876-12-14
56 rdf:type schema:CreativeWork
57 sg:pub.10.1186/s12967-016-0880-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041989489
58 https://doi.org/10.1186/s12967-016-0880-2
59 rdf:type schema:CreativeWork
60 https://www.grid.ac/institutes/grid.414527.1 schema:Organization
61 https://www.grid.ac/institutes/grid.414818.0 schema:Organization
 




Preview window. Press ESC to close (or click here)


...